JTO Clin Res Rep 2024 Feb
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Related Questions
New answer by Medical Oncologist at University of Colorado (June 20, 2025)
In general with TKIs, it is critical to consider mechanisms of resistance. Broadly speaking, these can be categorized as on-target (e.g. ALK G1202R), off-target (e.g. MET gene...